Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study
Serum calcium measured in 27,158 subjects in 1994 and the calcium-sensing receptor polymorphism rs17251221 genotyped in 9,404 subjects were related to cardiovascular risk factors, incident myocardial infarction (MI), type 2 diabetes (T2DM), cancer and death during follow-up until 2008–2010. In a Cox...
Published in: | European Journal of Epidemiology |
---|---|
Main Authors: | , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | unknown |
Published: |
Springer Netherlands
2013
|
Subjects: | |
Online Access: | https://doi.org/10.1007/s10654-013-9822-y |
id |
ftaustraliancuni:oai:acuresearchbank.acu.edu.au:8qzq3 |
---|---|
record_format |
openpolar |
spelling |
ftaustraliancuni:oai:acuresearchbank.acu.edu.au:8qzq3 2023-09-05T13:23:47+02:00 Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study Jorde, Rolf Schirmer, Henrik Njolstad, I. Loechen, Maja-Lisa Mathiesen, E. B. Kamycheva, Elena Figenschau, Yngve Grimnes, Guri 2013 https://doi.org/10.1007/s10654-013-9822-y unknown Springer Netherlands https://acuresearchbank.acu.edu.au/item/8qzq3/serum-calcium-and-the-calcium-sensing-receptor-polymorphism-rs17251221-in-relation-to-coronary-heart-disease-type-2-diabetes-cancer-and-mortality-the-troms-study ISSN:0393-2990 https://doi.org/10.1007/s10654-013-9822-y Jorde, Rolf, Schirmer, Henrik, Njolstad, I., Loechen, Maja-Lisa, Mathiesen, E. B., Kamycheva, Elena, Figenschau, Yngve and Grimnes, Guri. (2013). Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study. European Journal of Epidemiology. 28(7), pp. 569 - 578. https://doi.org/10.1007/s10654-013-9822-y Calcium-sensing receptor Cancer Cardiovascular disease Mortality Prostate cancer Serum calcium journal-article 2013 ftaustraliancuni https://doi.org/10.1007/s10654-013-9822-y 2023-08-11T14:32:03Z Serum calcium measured in 27,158 subjects in 1994 and the calcium-sensing receptor polymorphism rs17251221 genotyped in 9,404 subjects were related to cardiovascular risk factors, incident myocardial infarction (MI), type 2 diabetes (T2DM), cancer and death during follow-up until 2008–2010. In a Cox regression model with adjustment for age, gender, smoking and body mass index, subjects with serum calcium 2.50–2.60 mmol/L had a significantly increased risk of incident MI [n = 1,802, hazards ratio (HR) 1.40, 95 % confidence interval (CI) 1.18, 1.66] and T2DM (n = 705, HR 1.49, 95 % CI 1.15, 1.94) and a significantly reduced risk of cancer (n = 2,222, HR 0.73, 95 % CI 0.62, 0.86) as compared to subjects with serum calcium 2.20–2.29 mmol/L. For rs17251221 there was a mean difference in serum calcium of 0.05 mmol/L between major and minor homozygote genotypes. No consistent, significant relation between rs17251221 and risk factors or the major hard endpoints were found. The minor homozygote genotype (high serum calcium) had a significant twofold increased risk (HR 2.32, 95 % CI 1.24, 4.36) for prostate cancer, as compared to the major homozygote. This may be clinically important if confirmed in other cohorts. Article in Journal/Newspaper Tromsø Australian Catholic University: ACU Research Bank Tromsø European Journal of Epidemiology 28 7 569 578 |
institution |
Open Polar |
collection |
Australian Catholic University: ACU Research Bank |
op_collection_id |
ftaustraliancuni |
language |
unknown |
topic |
Calcium-sensing receptor Cancer Cardiovascular disease Mortality Prostate cancer Serum calcium |
spellingShingle |
Calcium-sensing receptor Cancer Cardiovascular disease Mortality Prostate cancer Serum calcium Jorde, Rolf Schirmer, Henrik Njolstad, I. Loechen, Maja-Lisa Mathiesen, E. B. Kamycheva, Elena Figenschau, Yngve Grimnes, Guri Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study |
topic_facet |
Calcium-sensing receptor Cancer Cardiovascular disease Mortality Prostate cancer Serum calcium |
description |
Serum calcium measured in 27,158 subjects in 1994 and the calcium-sensing receptor polymorphism rs17251221 genotyped in 9,404 subjects were related to cardiovascular risk factors, incident myocardial infarction (MI), type 2 diabetes (T2DM), cancer and death during follow-up until 2008–2010. In a Cox regression model with adjustment for age, gender, smoking and body mass index, subjects with serum calcium 2.50–2.60 mmol/L had a significantly increased risk of incident MI [n = 1,802, hazards ratio (HR) 1.40, 95 % confidence interval (CI) 1.18, 1.66] and T2DM (n = 705, HR 1.49, 95 % CI 1.15, 1.94) and a significantly reduced risk of cancer (n = 2,222, HR 0.73, 95 % CI 0.62, 0.86) as compared to subjects with serum calcium 2.20–2.29 mmol/L. For rs17251221 there was a mean difference in serum calcium of 0.05 mmol/L between major and minor homozygote genotypes. No consistent, significant relation between rs17251221 and risk factors or the major hard endpoints were found. The minor homozygote genotype (high serum calcium) had a significant twofold increased risk (HR 2.32, 95 % CI 1.24, 4.36) for prostate cancer, as compared to the major homozygote. This may be clinically important if confirmed in other cohorts. |
format |
Article in Journal/Newspaper |
author |
Jorde, Rolf Schirmer, Henrik Njolstad, I. Loechen, Maja-Lisa Mathiesen, E. B. Kamycheva, Elena Figenschau, Yngve Grimnes, Guri |
author_facet |
Jorde, Rolf Schirmer, Henrik Njolstad, I. Loechen, Maja-Lisa Mathiesen, E. B. Kamycheva, Elena Figenschau, Yngve Grimnes, Guri |
author_sort |
Jorde, Rolf |
title |
Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study |
title_short |
Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study |
title_full |
Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study |
title_fullStr |
Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study |
title_full_unstemmed |
Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study |
title_sort |
serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the tromsø study |
publisher |
Springer Netherlands |
publishDate |
2013 |
url |
https://doi.org/10.1007/s10654-013-9822-y |
geographic |
Tromsø |
geographic_facet |
Tromsø |
genre |
Tromsø |
genre_facet |
Tromsø |
op_relation |
https://acuresearchbank.acu.edu.au/item/8qzq3/serum-calcium-and-the-calcium-sensing-receptor-polymorphism-rs17251221-in-relation-to-coronary-heart-disease-type-2-diabetes-cancer-and-mortality-the-troms-study ISSN:0393-2990 https://doi.org/10.1007/s10654-013-9822-y Jorde, Rolf, Schirmer, Henrik, Njolstad, I., Loechen, Maja-Lisa, Mathiesen, E. B., Kamycheva, Elena, Figenschau, Yngve and Grimnes, Guri. (2013). Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: the Tromsø Study. European Journal of Epidemiology. 28(7), pp. 569 - 578. https://doi.org/10.1007/s10654-013-9822-y |
op_doi |
https://doi.org/10.1007/s10654-013-9822-y |
container_title |
European Journal of Epidemiology |
container_volume |
28 |
container_issue |
7 |
container_start_page |
569 |
op_container_end_page |
578 |
_version_ |
1776204360657666048 |